

PTO FAX NO.: 1-703-872-9306
ATTENTION: Examiner Walicka

Atty Docket No. 015270-006444US

Group Art Unit 1652

**OFFICIAL COMMUNICATION
FOR THE PERSONAL ATTENTION OF
EXAMINER WALICKA**

FAX RECEIVED

SEP 12 2002

GROUP 1600

OFFICIAL**CERTIFICATION OF FACSIMILE TRANSMISSION**


I hereby certify that the following documents are being transmitted via facsimile to the Patent and Trademark Office, facsimile number 1-703-872-9306, on the date shown below Application of John P. Anderson et al., Application No. 09/724,571, filed November 28, 2000 for BETA-SECRETASE ENZYME COMPOSITIONS AND METHODS.

Documents Attached

1. Transmittal (PTO/SB/21) (1 page); and,
2. Response to Restriction/Election Requirement and Amendment (6 pages).

Number of pages being transmitted, including this page: 8

Dated: September 11, 2002


Rosemarie L. Celli, Reg. No. 42,397

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY
RETURN FACSIMILE AT (650) 326-2422**

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, CA 94111-3834
Telephone: 650-326-2400
Fax: 650-326-2422

FA 3249428 v1

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-872-9306 on September 11, 2002.

PATENT
Attorney Docket No.: 015270-006444US
Client Ref. No.: 228-US-NEW2C4

TOWNSEND and TOWNSEND and CREW LLP

By: 

Rosemarie L. Celli, Reg. No. 42,397

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

John P. Anderson et al.

Application No.: 09/724,571

Filed: November 28, 2000

09/13/2002 GTRAHMEL 00000001 201430 09724571

For: BETA-SECRETASE ENZYME
COMPOSITIONS AND METHODS

Examiner: Walicka

Art Unit: 1652

SUPPLEMENTAL RESPONSE TO
RESTRICTION REQUIREMENT/ELECTION
OF SPECIES REQUIREMENT

&

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This paper supplements the response submitted on July 17, 2002 to the Restriction Requirement mailed January 17, 2002.

IN THE CLAIMS:

Please add new claims 132-134, and amend claims 78, 81, 84, and 85 as follows.

B¹
78. (Amended) A method of screening for compounds that inhibit A β production, comprising contacting a β -secretase polypeptide purified to apparent homogeneity comprising a polypeptide that (i) is fewer than about 450 amino acid residues in length, (ii) includes an amino acid sequence that is at least 90% identical to SEQ ID NO: 75 including conservative substitutions thereof, and (iii) exhibits β -secretase activity, as evidenced by an ability to cleave a substrate selected from the group consisting of the 695 amino acid isotype of beta amyloid precursor protein (β APP) between amino acids 596 and 597 thereof, MBP-C125wt